{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:06:08Z","timestamp":1770894368233,"version":"3.50.1"},"reference-count":43,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1185\/030079906x112688","type":"journal-article","created":{"date-parts":[[2006,5,27]],"date-time":"2006-05-27T14:29:22Z","timestamp":1148740162000},"page":"1249-1256","source":"Crossref","is-referenced-by-count":51,"title":["The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases"],"prefix":"10.1185","volume":"22","author":[{"given":"Eamonn","family":"Brankin","sequence":"first","affiliation":[{"name":"Coatbridge Local Health Care Co-operative, Coatbridge, Lanarkshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mel","family":"Walker","sequence":"additional","affiliation":[{"name":"Healthcare Management, Roche Products Limited, Welwyn Garden City, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niall","family":"Lynch","sequence":"additional","affiliation":[{"name":"Global Health Outcomes, GlaxoSmithKline, Greenford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence","family":"Aspray","sequence":"additional","affiliation":[{"name":"Institute for Ageing and Health, University of Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Lis","sequence":"additional","affiliation":[{"name":"Centre for Socioeconomic Research, UWIST, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warren","family":"Cowell","sequence":"additional","affiliation":[{"name":"Healthcare Management, Roche Products Limited, Welwyn Garden City, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2006,5,25]]},"reference":[{"key":"e_1_2_1_2_1","unstructured":"World Health Organization. Assessment of fracture risk and its application to screening for post menopausal osteoporosis. Technical report series 843. Geneva: World Health Organization; 1994"},{"key":"e_1_2_1_3_1","unstructured":"National Osteoporosis Society website: What is osteoporosis? Available from http:\/\/www.nos.org.uk [accessed 31st July 2005]"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050107"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.3111\/200104051062"},{"key":"e_1_2_1_6_1","unstructured":"Office for National Statistics. Population projections 1998-based 2000; Series PP2 no 22"},{"key":"e_1_2_1_7_1","unstructured":"Bailey K Ellis C Majeed A. Trends in the treatment of osteoporosis and types of drug treatment prescribed in general practice in England and Wales 1994\u20131998. Health Statistics Quarterly 2002;16: 5\u201313"},{"key":"e_1_2_1_8_1","unstructured":"The National Institute for Clinical Excellence. Bisphosphonates (alendronate etidronate risedronate) selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Final appraisal determination (2004). Available from http:\/\/www.nice.org.uk [accessed 30 Nov 2005]"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1502-4"},{"key":"e_1_2_1_10_1","first-page":"271","article-title":"McLaughlin-Miley C, Shi J","volume":"48","author":"McCombs JS","year":"2004","unstructured":"McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271\u201387","journal-title":"Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1431-2"},{"key":"e_1_2_1_12_1","first-page":"859","article-title":"Ish-Shalom, S","volume":"5","author":"Segal E","year":"2003","unstructured":"Segal E, Tamir A, Ish-Shalom, S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003;5:859\u201362","journal-title":"Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J"},{"key":"e_1_2_1_13_1","unstructured":"Lombas C Hakim C Zanchetta JR. Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 2001;15:S529 [abstract M406]"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1652-z"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(97)80018-5"},{"key":"e_1_2_1_16_1","first-page":"1421","article-title":"Factors affecting patient compliance with antihyperlipidemic medications in an HMO Population","volume":"4","author":"Sung JC","year":"1998","unstructured":"Sung JC, Nichol MB, Venturini F, et al. Factors affecting patient compliance with antihyperlipidemic medications in an HMO Population. Am J Manag Care 1998;4:1421\u201330","journal-title":"Am J Manag Care"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198010000-00002"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.18.1458"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2003.9.5.424"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.4.455"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199711000-00008"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00467-1"},{"key":"e_1_2_1_23_1","first-page":"856","article-title":"MacCosbe PE","volume":"80","author":"Recker R","year":"2005","unstructured":"Recker R, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856\u201361","journal-title":"Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X61875"},{"key":"e_1_2_1_25_1","unstructured":"Sebaldt RJ Shane LG Pham BZ et al. Impact of non-compliance and non-persistence with daily-regimen bisphosphonates on longer term effectiveness outcomes in patients with osteoporosis. Poster M423 presented at: the 26th Annual Meeting of the American Society for Bone Mineral Research October 1\u20135 2004 Seattle"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(03)00362-0"},{"key":"e_1_2_1_27_1","first-page":"259","article-title":"Taggart H","volume":"14","author":"Hamilton B","year":"2003","unstructured":"Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporosis Int 2003;14:259\u201362","journal-title":"Tolerability and compliance with risedronate in clinical practice. Osteoporosis Int"},{"key":"e_1_2_1_28_1","unstructured":"International Osteoporosis Foundation. The adherence gap: why osteoporosis patients don\u2019t continue with treatment. A European report highlighting the gap between the beliefs of people with osteoporosis and the perceptions of their physicians. 2005"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(97)80122-1"},{"key":"e_1_2_1_30_1","unstructured":"De Wilde S Carey JM Bremner SA. A comparison of the recording of 30 common childhood conditions in the Doctors\u2019 Independent Network and General Practice Research Databases. Health Statistics Quarterly 2004;22: 21\u201330"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2630010607"},{"key":"e_1_2_1_32_1","doi-asserted-by":"crossref","unstructured":"Lawrence M Coulter A Jones L. A total audit of preventative procedures in 45 practices caring for 430 000 patients. Br Med J 1990;300: 1501\u20133","DOI":"10.1136\/bmj.300.6738.1501"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.4.417"},{"key":"e_1_2_1_34_1","first-page":"P\u2013297","article-title":"Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study","volume":"72","author":"Eastell R","year":"2003","unstructured":"Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 2003;72:P\u2013297","journal-title":"Calcif Tissue Int"},{"key":"e_1_2_1_35_1","unstructured":"Finigan J Bainbridge PR Eastell R. Adherence to osteoporosis therapies. Osteoporosis Int 2001;12:S48\u20139 [abstract P110)]"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.1998.4.5.488"},{"key":"e_1_2_1_37_1","unstructured":"Boccuzzi SJ Folz SH Omar MA Kahler KH. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporosis Int 2005;16\\(Suppl 4): S35\u201336 [abstract P7.10]"},{"key":"e_1_2_1_38_1","unstructured":"Ettinger MP Gallagher R Amonkar M. Medication persistence is improved with less frequent dosing of bisphosphonates but remains inadequate. Arthritis Rheum 2004;15(Suppl):S513 [abstract 1325]"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80085-6"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X74862"},{"key":"e_1_2_1_41_1","unstructured":"Thompson PW Cooper C Carr AJ. Factors influencing adherence to bisphosphonates for osteoporosis. Arthritis Rheum 2005;52(Suppl):S257\u2013S258"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X61875"},{"key":"e_1_2_1_43_1","first-page":"475","article-title":"Munro R; Lanarkshire Osteoporosis Service","volume":"21","author":"Brankin E","year":"2005","unstructured":"Brankin E, Mitchell C, Munro R; Lanarkshire Osteoporosis Service. Closing the osteoporosis management gap on primary care: a secondary prevention of fracture programme. Curr Med Res Opin 2005;21:475\u201382","journal-title":"Closing the osteoporosis management gap on primary care: a secondary prevention of fracture programme. Curr Med Res Opin"},{"issue":"348","key":"e_1_2_1_44_1","first-page":"383","article-title":"Kanani R","volume":"10","author":"Haynes RB","year":"1996","unstructured":"Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996;10;348:383\u20136","journal-title":"Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/030079906X112688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:09:25Z","timestamp":1770890965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/030079906X112688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,25]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1185\/030079906X112688"],"URL":"https:\/\/doi.org\/10.1185\/030079906x112688","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,25]]}}}